Bionomics (BNO)

Shares / Stock Code


Stock Exchange / Sharemarket


Bionomics (BNO) is a biotechnology company creating small molecule drugs to treat cancer and disorders of the central nervous system. The company has drug discovery programs in four therapeutic areas: Cancer (Vascular Targeting Agents), Multiple Scelrosis, Anxiety/Epilepsy and Cancer (Angiogenesis). Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers to development treatments for cancer and serious disorders of the nervous system. Initially technology platforms were established in the genomics of epilepsy, angiogenesis and breast cancer. In 2005 the company acquired Neurofit Preclinical Research and Lliad Chemicals. As a result BNO has proprietary technologies for each step in the drug discovery process.

BNO became the first company in the world to develop a genetic test for Severe Myoclonic Epilepsy of Infants. Also in using its Angene cancer target discovery platform BNO has identified over 150 human genes implicated in angiogenesis, the process whereby tissue recruits new blood vessels for growth. Angiogenesis is associated with a range of diseases including cancer and eye disease.

Bionomics (BNO) Products and Services

  • Developer of innovative treatments for cancer

Bionomics (BNO) Locations and Subsidiaries

Bionomics Head Office
31 Dalgleish Street,
SA 5031

Phone: 08 8354 6100
Fax: 08 8354 6199

Bionomics (BNO) Share Price

Submitted by ASX Listed Company on 2 March, 2010 - 07:00